Mankyu Park
Directeur/Membre du Conseil chez Coagulant Therapeutics, Inc.
Postes actifs de Mankyu Park
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Coagulant Therapeutics, Inc.
 Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Mankyu Park
Anciens postes connus de Mankyu Park
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| DTCP Management GmbH | Corporate Officer/Principal | - | - |
Formation de Mankyu Park
| Goizueta Business School-Emory | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Corée du Sud | 2 |
Opérationnelle
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Consumer Services | 2 |
| Finance | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
| DTCP Management GmbH | Finance |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Health Technology |
- Bourse
- Insiders
- Mankyu Park
- Expérience